Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 25.08.2025 2 Am J Pathol 2 Am J Respir Crit Care Med 2 Ann Surg Oncol 1 Ann Thorac Surg 4 BMC Cancer 3 Br J Cancer 1 Cancer 1 Cancer Res 1 Clin Cancer Res 3 Clin Lung Cancer 1 Clin Nucl Med 3 Eur J Cancer 1 Eur J Cardiothorac Surg 1 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 2 J Clin Oncol 2 J Natl Cancer Inst 1 J Surg Oncol 1 J Thorac Cardiovasc Surg 1 J Thorac Oncol 3 Lung Cancer 1 Lung Cancer (Auckl) 2 Mol Carcinog 1 N Engl J Med 3 Nat Med 1 Oncol Rep 2 Oncologist 1 PLoS Genet 4 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. WEI B, Li A, Zhao G, Liu R, et al
   Single-Cell Sequencing Reveals the Palmitoylation Landscape in Lung Adenocarcinoma and Identifies ABHD17C as a Novel Biomarker.
   Am J Pathol. 2025;195:1575-1587.
   PubMed         Abstract available
   
   
2. MIYATA-MORITA K, Kawashima A, Kiriya M, Dejima H, et al
   Perilipin 2 Mediates Progression of Lung Adenocarcinoma by Modulating Lipid Metabolism.
   Am J Pathol. 2025;195:1588-1599.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

3. MADRIGAL JM, Fisher JA, Pruitt CN, Liao LM, et al
   Reply to Zhou et al.: Methodological Pitfalls Undermine Industrial Emission-related Lung Cancer Risk Assessment.
   Am J Respir Crit Care Med. 2025 Aug 22. doi: 10.1164/rccm.202507-1584.
   PubMed        
   
   
4. ZHOU D, Wang H, Xiaoli Z
   Methodological Pitfalls Undermine Industrial Emission-related Lung Cancer Risk Assessment.
   Am J Respir Crit Care Med. 2025 Aug 22. doi: 10.1164/rccm.202506-1451.
   PubMed        
   
   

   
   Ann Surg Oncol

5. LIU J, Ma H, Li D, Li Y, et al
   Early Post-discharge Pain Trajectories After Thoracoscopic Sublobar Resection for Stage IA Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Aug 25. doi: 10.1245/s10434-025-18183.
   PubMed         Abstract available
   
   
6. SONODA D, Kondo Y, Maruyama R, Mitsuhashi S, et al
   Characteristics of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation.
   Ann Surg Oncol. 2025 Aug 24. doi: 10.1245/s10434-025-18143.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

7. VELOTTA JB, Burapachaisri K, Baskin AS, Zhu Z, et al
   The Importance of Lay Navigators in Lung Cancer Screening Among Asian Americans in an Integrated Healthcare System.
   Ann Thorac Surg. 2025 Aug 20:S0003-4975(25)00761.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. WANG X, Liang H, Du Q, Li Y, et al
   HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis.
   BMC Cancer. 2025;25:1317.
   PubMed         Abstract available
   
   
9. ZHAO W, Li B, Gu Y, Jin X, et al
   The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis.
   BMC Cancer. 2025;25:1332.
   PubMed         Abstract available
   
   
10. OUYANG T, Zhang F, Yang Y, Luo T, et al
    Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers.
    BMC Cancer. 2025;25:1353.
    PubMed         Abstract available
    
    
11. TAN Y, Song Q
    Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system.
    BMC Cancer. 2025;25:1360.
    PubMed         Abstract available
    
    

    
    Br J Cancer

12. GONG B, Guo Y, Wan Q, Lou J, et al
    The lung immune prognostic index stratifies the occurrence of checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients: a multi-institutional cohort study.
    Br J Cancer. 2025 Aug 15. doi: 10.1038/s41416-025-03124.
    PubMed         Abstract available
    
    
13. LI J, Liu Y, Zhang L, Xing Y, et al
    An intelligent diagnostic model for pulmonary nodules utilizing chest radiographic imagery and its application in community-based lung cancer screening.
    Br J Cancer. 2025 Aug 22. doi: 10.1038/s41416-025-03147.
    PubMed         Abstract available
    
    
14. ROCCA A, Crino L, Braga L, Salton F, et al
    Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies.
    Br J Cancer. 2025 Aug 23. doi: 10.1038/s41416-025-03139.
    PubMed         Abstract available
    
    

    
    Cancer

15. FLOREZ N, Patel S, Wakelee HA, Rotow J, et al
    Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.
    Cancer. 2025;131:e70060.
    PubMed         Abstract available
    
    

    
    Cancer Res

16. ZHAO J, Zhang W, Zeng Y, Lu D, et al
    Targeting ATP7A-Dependent Copper Metabolic Homeostasis Induces Cuproptosis and Suppresses the Progression of Mutant KRAS-Driven Lung Cancer.
    Cancer Res. 2025 Aug 21. doi: 10.1158/0008-5472.CAN-24-2558.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

17. GAO R, Lou N, Yang S, Yang M, et al
    Multi-Omics and Single-Cell Insights Reveal a Lysophosphatidic Acid (LPA)-Mediated Resistant Mechanism to Third Generation EGFR-TKI in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0993.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

18. HATA T, Yamada T, Furuya N, Tanaka H, et al
    Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
    Clin Lung Cancer. 2025 Jul 22:S1525-7304(25)00158.
    PubMed         Abstract available
    
    
19. YOO YJ, Song SY, Shin YS, Kim SS, et al
    What is the Optimal Dose and Fractionation Schedule for Inoperable Node-Negative Large (>/= 5 cm) Non-Small Cell Lung Cancer?
    Clin Lung Cancer. 2025 Jul 29:S1525-7304(25)00162.
    PubMed         Abstract available
    
    
20. STOVER AM, Deal AM, Medley CJ, Weiner AA, et al
    Feasibility, Acceptability, and Utility of Remote Patient-Reported Outcomes Monitoring in Patients With Lung Cancer: A Moovcare(c) Study.
    Clin Lung Cancer. 2025 Aug 5:S1525-7304(25)00160.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

21. ZHAO R, Liu J, Liang W, Li D, et al
    PSMA PET/CT for Improved Staging Accuracy and Imaging of Neovascularization-associated Features in Primary Lung Cancer.
    Clin Nucl Med. 2025 Jul 29. doi: 10.1097/RLU.0000000000006061.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

22. MURO K, Feinstein T, Baranda J, Bonta I, et al
    Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.
    Eur J Cancer. 2025;227:115603.
    PubMed         Abstract available
    
    
23. PRABHASH K, Noronha V, Patil V, Menon N, et al
    A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer.
    Eur J Cancer. 2025;228:115730.
    PubMed         Abstract available
    
    
24. GALLINA FT, Marinelli D, Taje R, Visca P, et al
    TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.
    Eur J Cancer. 2025;227:115622.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

25. BEUSHAUSEN C, D'Ambrosio PD, Costa R, Cmelak L, et al
    Sex differences in health-related quality of life following pulmonary resection: a systematic review.
    Eur J Cardiothorac Surg. 2025 Aug 4:ezaf271. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Int J Cancer

26. ZHANG Q, Fu Q, Hou Y, Lv Y, et al
    Advances in CAR-T therapy for small cell lung cancer.
    Int J Cancer. 2025 Aug 18. doi: 10.1002/ijc.70093.
    PubMed         Abstract available
    
    

    
    Int J Oncol

27. WANG F, Hu S, Bian J, Gao Q, et al
    Notch3 mediated TGF?beta1 activation enhances epithelial?mesenchymal transition and cancer stemness in non?small lung cancer.
    Int J Oncol. 2025;67:85.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

28. WANG W, Ren M, Ren J, Dang J, et al
    Predicting Radiation Pneumonitis Integrating Clinical Information, Medical Text, and 2.5D Deep Learning Features in Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Aug 21:S0360-3016(25)06035.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

29. PEROL M, Li W, Lai RK, Zhou C, et al
    Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?".
    J Clin Oncol. 2025 Aug 21:JCO2501448. doi: 10.1200/JCO-25-01448.
    PubMed        
    
    
30. WANG Z, Zhu X
    Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?
    J Clin Oncol. 2025 Aug 21:JCO2501055. doi: 10.1200/JCO-25-01055.
    PubMed        
    
    

    
    J Natl Cancer Inst

31. FULLER S, Alexeeff S, Caan B, Goncalves MD, et al
    Early identification of weight loss trajectories in advanced cancer and associations with survival.
    J Natl Cancer Inst. 2025;117:1729-1732.
    PubMed         Abstract available
    
    
32. PATON EL, Cetnar JP, Freeman-Daily J, Feldman J, et al
    Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor-associated adverse events.
    J Natl Cancer Inst. 2025;117:1664-1672.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

33. MOUSAVI SE, Yarahmadi D
    Comment On: "Clinical Course After Radical Local Therapy for Oligo-Recurrence of Nonsmall Cell Lung Cancer".
    J Surg Oncol. 2025 Aug 18. doi: 10.1002/jso.28153.
    PubMed        
    
    

    
    J Thorac Cardiovasc Surg

34. CHRISTIE I, Luketich JD, Schuchert MJ, Slingerland A, et al
    Image-guided Radiofrequency Ablation for Treatment of Stage I Non-Small Cell Lung Cancer in 111 High-risk Patients: Analysis of Prognostic Variables.
    J Thorac Cardiovasc Surg. 2025 Aug 20:S0022-5223(25)00669.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

35. KENMOTSU H, Saito Y, Ninomiya K, Uematsu S, et al
    Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME).
    J Thorac Oncol. 2025 Aug 18:S1556-0864(25)01014.
    PubMed         Abstract available
    
    

    
    Lung Cancer

36. CHEN L, Zhang XH, Mao ZJ, Wang D, et al
    Clinical outcomes and neuroendocrine features of transformed versus primary small-cell lung cancer.
    Lung Cancer. 2025;207:108714.
    PubMed         Abstract available
    
    
37. NEYT M, Luyten J, Desimpel F, Camberlin C, et al
    An economic evaluation of lung cancer screening with low-dose computed tomography in a high-risk population of (ex-)smokers in Belgium.
    Lung Cancer. 2025;207:108697.
    PubMed         Abstract available
    
    
38. GRAABAK G, Halvorsen TO, Gronberg BH, Killingberg KT, et al
    Changes in use of radiotherapy for lung cancer - A Norwegian population-based study from 2000 until 2020.
    Lung Cancer. 2025;207:108720.
    PubMed         Abstract available
    
    

    
    Lung Cancer (Auckl)

39. DESCOURT R, Guisier F, Perol M, Cadranel J, et al
    Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study).
    Lung Cancer (Auckl). 2025;16:107-114.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

40. QIAN D, Zha D, Sang Y, Tao J, et al
    A-to-I RNA Edited miR-3167 Restrains Malignant Behaviors of Lung Adenocarcinoma by Influencing SSR2-Meditated Hippo Signaling.
    Mol Carcinog. 2025;64:1552-1563.
    PubMed         Abstract available
    
    
41. XU S, Chen C, Liu H, Jiang S, et al
    Osteoglycin Inhibits the Progression of Lung Adenocarcinoma by Modulating ICAM1-Mediated Cell Adhesion via the PI3K/AKT Pathway.
    Mol Carcinog. 2025;64:1564-1579.
    PubMed         Abstract available
    
    

    
    N Engl J Med

42. CALVO V
    Redefining Lung Cancer Therapy - A Long-Awaited Shift in Strategy.
    N Engl J Med. 2025;393:809-810.
    PubMed        
    
    

    
    Nat Med

43. HONG S, Wang Q, Cheng Y, Luo Y, et al
    First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.
    Nat Med. 2025 Aug 19. doi: 10.1038/s41591-025-03883.
    PubMed         Abstract available
    
    
44. PREUSSER M, Garde-Noguera J, Garcia-Mosquera JJ, Gion M, et al
    Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.
    Nat Med. 2025;31:2797-2805.
    PubMed         Abstract available
    
    
45. CHO BC, Lu S, Lee MA, Song Z, et al
    D3S-001 in advanced solid tumors with KRAS(G12C) mutations: a phase 1 trial.
    Nat Med. 2025;31:2768-2777.
    PubMed         Abstract available
    
    

    
    Oncol Rep

46. WU A, Ni Y, Zhou Y, Shi J, et al
    Emerging dual role of ferroptosis in lung cancer (Review).
    Oncol Rep. 2025;54:141.
    PubMed         Abstract available
    
    

    
    Oncologist

47. VELCHETI V, Sun X, Hanna M, Zimmerman NM, et al
    Predictors of outcomes in advanced non-small cell lung cancer treated with pembrolizumab maintenance.
    Oncologist. 2025;30:oyaf070.
    PubMed         Abstract available
    
    
48. WANG J, Sajeev G, Chai X, Takundwa R, et al
    Efficacy Outcomes Between Tarlatamab and Real-World Physicians' Choice of Therapies for Previously Treated Extensive Stage Small Cell Lung Cancer.
    Oncologist. 2025 Aug 21:oyaf256. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS Genet

49. LYU Z, Si G, Xing M, Li W, et al
    Circulating proteins associated with histological subtypes of lung cancer from genetic and population-based perspectives.
    PLoS Genet. 2025;21:e1011821.
    PubMed         Abstract available
    
    

    
    PLoS One

50. SUN J, Yang L, Liu D, Xue H, et al
    Diagnostic accuracy of circulating tumor DNA for detection of ALK rearrangement in lung cancer: A systematic review and meta-analysis of 14 studies.
    PLoS One. 2025;20:e0330855.
    PubMed         Abstract available
    
    
51. CHEN L, Zhou M, Lv D, Qiu S, et al
    The association between cadmium exposure and lung cancer risk: A protocol for systematic review and meta-analysis.
    PLoS One. 2025;20:e0329660.
    PubMed         Abstract available
    
    
52. 
    Correction: Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.
    PLoS One. 2025;20:e0330646.
    PubMed         Abstract available
    
    
53. 
    Retraction: Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells.
    PLoS One. 2025;20:e0330467.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.